

Heme Malignancy Disease-Oriented Team

Clinical Research Treatment Trial Flowchart

Clinical Research Managers:

Stephanie Osorio
Judit Castellanos

Clinical Research Coordinators:

Alice Ting
Michael Kunicki
Kelsey McAbee
Georgina Alvarez-Diaz
Melisa Duvnjak
Makena Castillo

Data Coordinators:

Heather Franson
Mario Diaz
Sarahy Martinez

Newly diagnosed

■ Open to Accrual
 ■ Low Accruing
 ■ Pending Activation/Suspended

Front Line

UCI 24-121

ASTX030 in Subjects w/Myeloid Neoplasm or in Combo w/Venetoclax in Subjects w/AML or MDS

Accrual: 4/5

Coord: Georgina Alvarez-Diaz

ETCTN 10675

A Randomized Phase II Trial of ASTX727 +/- ladamostat in Accelerated/Blast-Phase Philadelphia Chromosome-Negative Myeloproliferative Neoplasms (MPNs)

Accrual: 0/5

Coord: Georgina Alvarez-Diaz

Supportive Care

UCI 20-50

N-Acetylcysteine in MPN to Improve Disease Markers & Symptoms

Accrual 14/27

Coord: Kelsey McAbee

UCI 26-12

A Phase 3 Randomized, Double-blind, Placebo-controlled Global Study of Sapablursen in Polycythemia Vera

Accrual:0

Coord: TBA

Newly diagnosed

UCI 24-121

ASTX030 in Subjects w/Myeloid Neoplasm or in Combo w/Venetoclax in Subjects w/AML or MDS

Accrual: 4/5

Coord: : Georgina Alvarez-Diaz

High-Risk

MM1MDS-A01

A Randomized Phase II Trial of Enasidenib-Based Therapies Versus Cedazuridine-Decitabine in Higher-Risk IDH2-Mutated Myelodysplastic Syndrome: A MyeloMATCH Sub-Study

Accrual: 0/5

Coord: Georgina Alvarez-Diaz

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

Low-Risk

Molecularly-Driven

HSCt

Relapsed/Refractory

Low-Risk

UCI 21-239

IRAK 1/4 inhibitor, R289, in patients w/ refractory or resistant lower-risk MDS

Accrual: 2/5

Coord: Georgina Alvarez-Diaz

UCI 25-193

ICP-248 in Combination with Azacitidine for the Treatment in Patients with Myeloid Malignancies

Accrual: 0/7

Coord: TBD

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

Molecularly-Driven

High-Risk

Newly diagnosed

Intensive

ETCTN-10596

SNDX-5613 + Daunorubicin and Cytarabine in Newly Diagnosed Acute Myeloid Leukemia (NPM1 Mutated/FLT3 Wildtype with Higher-Risk Features or MLL/KMT2A Rearranged)

Accrual: 0/5

Coord: Stephanie TBA

MYELOMATCH

MYELOMATCH, Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI MyeloMATCH Clinical Trials

Accrual: 0/5

Coord: Georgina Alvarez-Diaz

■ Open to Accrual
 ■ Low Accruing
 ■ Pending Activation/Suspended

Non-Intensive

KMT2A-r/NPM1-m

UCI 23-44

Venetoclax/Azacitidine v.s Venetoclax+ KO-530 v.s cytarabine/daunorubicin (7+3)+ KO-539 in AML

Accrual: 9/10

Coord: Georgina Alvarez-Diaz

FLT3 mutation

UCI 21-216 (suspended)

Giltertinib+Venetoclax+Azacitidine in patients w/ FLT3 mutant AML not eligible for intensive induction chemotherapy

Accrual: 2/5

Coord: Stephanie Osorio

ETCTN-10630

Ladademstat in Combination with Venetoclax and Azacitidine in Patients with Post MDS Transformation to AML

Accrual: 2/7

Coord: TBA

UCI 24-121

ASTX030 in Subjects w/Myeloid Neoplasm or in Combo w/Venetoclax in Subjects w/AML or MDS

Accrual: 4/5

Coord: Georgina Alvarez-Diaz

UCI 22-81

HM43239 in patients w/ R/R AML

Accrual: 3/6

Coord: Georgina Alvarez-Diaz

Newly diagnosed

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

KMT2A-r/NPM1-m

UCI 25-20

Assessing Ziftomenib in
Combination with Either
Standard of Care
Nonintensive
(Venetoclax+Azacitidine) or
Intensive (7+3) Therapy in
Patients with Untreated
NPM1 Mutated or KMT2A
Rearranged AML

Accrual: 1/5

Coord: Georgina Alvarez-Diaz

Relapsed/Refractory

2nd Line+

UCI 22-81

HM43239 in patients w/ R/R
AML

Accrual: 3/6

Coord: Georgina Alvarez-Diaz

≤1 Line Only

UCI 25-105

LYT-200 in patients w/ R/R
AML or high-risk MDS

Accrual: 0/5

Coord: TBA

Non-Intensive

UCI 25-193

ICP-248 in Combination
with Azacitidine for the
Treatment in Patients
with Myeloid
Malignancies

Accrual: 0/7

Coord: Georgina Diaz

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

Molecularly-Driven

Relapsed/Refractory

Molecularly-Driven

KMT2A-r/NPM1-m

UCI 23-44

Venetoclax/Azacitidine v.s
Venetoclax+ KO-530 v.s
cytarabine/daunorubicin (7+3)+
KO-539 in AML

Accrual: 9/10

Coord: Georgina Alvarez-Diaz

UCI 23-154

Ziftomenib combinations for
the KMT2A-rearranged/NPM1
mutant R/R AML

Accrual: 3/5

Coord: Georgina Alvarez-Diaz

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

Maintenance

High-Risk, HSCT

Salvage Therapy

Newly Diagnosed

■ Open to Accrual
 ■ Low Accruing
 ■ Pending Activation/Suspended

Ph+ only

Ph- only

Age ≥ 18 years & < 40 years,
CD22+ (≥ 20%)

Age ≥ 18 years

SWOG-21CTP-LEUK01

Phase II Trial of Asciminib, Dasatinib, Prednisone, and Blinatumomab for Participants with Newly Dx Ph+ B-ALL

Accrual: 1/5
Coord: Makena Belle Castillo

A041501

Addition of Inotuzumab Ozogamicin to frontline therapy in young adults (18-39y/o)

Accrual: 10/15
Coord: Makena Belle Castillo

UCI 25-104 (NEW)

subcutaneous blinatumomab vs. intravenous blinatumomab in newly diagnosed adults with (Ph)- B cell precursor ALL

Accrual: 0/5
Coord: Makena Belle Castillo

Relapsed/Refractory

■ Open to Accrual
 ■ Low Accruing
 ■ Pending Activation/Suspended

Ph+ only

Ph- only

Age ≥ 12 y/o & CD19+

Age ≥ 18 y/o & CD22+

26-53 (New)

A phase 2/3, Randomized, Open-Label, Comparison Study of MK-1045 Versus Blinatumomab in participants with Relapsed or Refractory CD19+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Accrual: 0/5

Coord: Makena Belle Castillo

UCI 25-209 (NEW)

UCART22 (allogeneic Anti-CD22 CAR-T) in R/R CD22+ B-ALL

Accrual: 0/3

Coord: Michael Kunicki

Newly diagnosed

UCI 25-166 (NEW)

QTX-2101 in Newly Diagnosed
Acute Promyelocytic Leukemia

Accrual: 0/5

Coord: Georgina Diaz

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

Newly diagnosed

UCI 23-189

Frontline Ruxolitinib with De-Intensified HLH-94 for Adults with Hemophagocytic Lymphohistiocytosis (HLH)

Accrual: 0/6

Coord: TBA

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

Relapsed/Refractory

2nd Line+

UCI 23-167

Phase I- TERN-701 in patients
w/CML

Accrual: 2/5

Coord: Kelsey McAbee

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

Newly Diagnosed

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

S2213 (RA SIGNOFF)

A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis

Accrual: 0/5
CRC: Alice Ting

Newly Diagnosed

UCI 24-170

Intravenous Gammagard Liquid (Immune Globulin Infusion, 10%) for Primary Infection Prophylaxis Compared With Secondary Infection Prophylaxis in Adult Subjects With Multiple Myeloma Receiving B-Cell Maturation Antigen×CD3–Directed Bispecific Antibody Therapy
Accrual: 0/10

Coord: Alice Ting

UCI 25-221 (NEW)

A Phase III, Multicentre Study to Evaluate Consolidation Treatment with AZD0120 vs ASCT, in Participants with Newly Diagnosed Multiple Myeloma who are Transplant Eligible

Accrual: TBA

Coord: TBA

Bispecific**UCI 23-158**

Phase I/II Study of Linvoseltamab (Anti-BCMA X Anti-CD3 Bispecific Antibody) in Previously Untreated Patients with Symptomatic Multiple Myeloma

Accrual: 2/6 (opened 3/29/24)

Coord: Alice Ting

UCI 25-220 (NEW)

A Phase III Open-Label, Randomised, Multicentre Study of Consolidation with a Single Administration of AZD0120 Compared with Continuous Standard Therapy in Participants with NDMM Who Are Not Planned to Receive ASCT as Initial Therapy

Accrual: 0/5

Coord: TBA

Open to Accrual

Low Accruing

Pending Activation/Suspended

Post ASCT

Front Line

High-Risk

Relapsed/Refractory

UCI 25-116

ANTITUMOR ACTIVITY OF
SIM0500, IN PARTICIPANTS
WITH R/R MULTIPLE MYELOMA

Accrual: 0/3

Coord: Judit Castellanos,
Stephanie Osorio

UCI 24-170

Ph III Gammagard Liquid for
Primary Infection Prophylaxis Vs
Secondary Infection prophylaxis
in MM

Accrual: 0/10

Coord: Alice Ting

UCI 26-33 (NEW)

Expanded Access Program for
Mezigdomide (in combination
with Carfilzomib/dex or
Bortezomib/dex) For Patients
with Relapsed/Refractory
Multiple Myeloma

(RRMM) Accrual: 0/7

Coord: Alice Ting

UCI 26-52 (NEW)

A Phase IB, Multi-center, study of
talquetamab in combination with
iderdomide and Dexamethasone
for the treatment of Relapsed or
Refractory Multiple Myeloma

Accrual: 0/5

Coord: Stephanie Osorio

■ Open to Accrual

■ Low Accruing

■ Pending Activation/Suspended

Molecularly-Driven

3rd Line+

UCI 25-62 (NEW)

EXPANDED ACCESS
PROTOCOL (EAP) FOR
SUBJECTS RECEIVING
IDECABTAGENE VICLEUCEL
THAT IS NONCONFORMING
FOR COMMERCIAL RELEASE

Accrual: 0/5

Coord: Michael Kunicki

ALLIANCE-A062102

Iberdomide Maintenance
Therapy Following
Idecabtagene Vicleucel CAR-T
in R/R MM

Accrual: 0/5

Coord: Michael Kunicki

UCI 26-07 (NEW)

Phase 3 Randomized Study Comparing JNJ-
79635322 versus Teclistamab in
Participants with Relapsed or Refractory
Multiple Myeloma who Have Received 1-3
Prior Lines of Therapy

Accrual: 0/5

Coord: TBA

2nd Line+

Maintenance

Other

UCI 26-51 (NEW)

A Phase 3, Prospective, Open-label multicenter, single-arm study to investigate the efficacy, safety and pharmacokinetics of IgPro20 in Subjects with Secondary Immune Deficiency due to Hematologic

Accrual: TBD

Coord: Stephanie Osorio

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

Relapsed/Refractory

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

ETCTN-10717 (New)

Accrual: 0/2

Coord: Melisa Duvnjak

Newly diagnosed

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

S1918 (SUSPENDED)

R-miniCHOP w/ or w/o oral Azacitidine
in patients 75 y/o or older

Accrual: 5/10

Coord: Melisa Duvnjak

UCI 23-19 (OPEN TO ACCRUAL)

PhIII Odronextamab Comb w/CHOP vs
Rituximab Comb w/CHOP

Accrual: 0/5

Coord: Melisa D.

UCI 24-22 (OPEN TO ACCRUAL)

Loncastuximab Tesirine and Rituximab
(Lonca-R) Followed by DA-EPOCH-R in
Previously Untreated High-risk Diffuse
Large B-cell Lymphoma

Accrual: 0/1

Coord: Melissa D.

26-59 (New)

A Phase III study to Evaluate The Efficacy
of Surovatamig Combined with Rituximab,
Cyclophosphamide, Doxorubicin,
Vincristine, and Prednisone (R-Chop) in
previously untreated Large B-Cell
Lymphoma

Accrual: 0/3

Coord: Stephanie Osorio

Relapsed/Refractory

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

Primary Relapsed/Refractory

Secondary Relapsed/Refractory

UCI 20-126 (suspended)

CB-010, CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy

Accrual: 7/10

Coord: Michael K.

Relapsed/Refractory

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

Molecularly-Driven

Tertiary Relapsed/Refractory

S2114

Consolidation therapy
following CD19 CAR T-cell tx

Accrual: 0/6

Coord: Michael Kunicki

2+ Lines

UCI 23-114

Safety and Efficacy of IMPT-314, a
CD19/20 Bispecific Chimeric Antigen
Receptor (CAR) T Cell Therapy in B-cell
NHL

Accrual: 9/10

Coord: Michael Kunicki

MRD+ Consolidation/Pre-Emptive Therapy

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

26-64 (New)

A randomized, Open Label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants with Minimal Residual Disease After Response to First Line therapy for Large B-Cell Lymphoma (Alpha3)

Accrual: 0/3

Coord: Judit Castellanos, Stephanie Osorio

Newly diagnosed

Low Grade

SWOG S2308

MOSUNETUZUMAB VS.
RITUXIMAB FOR LOW TUMOR
BURDEN FOLLICULAR
LYMPHOMA

Accrual: 0/5

Coord: Melisa Duvnjak

≥75 years

S1918 (SUSPENDED)

R-miniCHOP w/ or w/o oral
Azacitidine in patients 75 y/o or
older

Accrual: 5/10

Coord: Melisa Duvnjak

■ Open to Accrual

■ Low Accruing

■ Pending Activation/Suspended

Relapsed/Refractory

■ Open to Accrual
 ■ Low Accruing
 ■ Pending Activation/Suspended

2nd Line+

UCI 22-134

Oral AS-1763 in patients w/
previously treated CLL/SLL or
NHL

Accrual: 5/9

Coord: Kelsey McAbee

3rd Line+

Consolidation

S2114

Consolidation therapy
following CD19 CAR T-cell tx

Accrual: 1/6

Coord: Michael Kunicki

Maintenance

UCI 21-95

Acalabrutinib Maintenance
Following Cellular Therapy for
LBCL Patients at High Risk for
Relapse

Accrual: 0/5

Coord: Michael Kunicki

Cell Therapy

UCI 23-114

Safety and Efficacy of IMPT-314, a
CD19/20 Bispecific Chimeric Antigen
Receptor (CAR) T Cell Therapy in B-cell
NHL

Accrual: 9/10

Coord: Michael Kunicki

UCI 25-63

EAP for Lisocabtagene Maraleucel
(liso-cel) that is Nonconforming for
Commercial Release

Accrual: TBD

Coord: Michael Kunicki

UCI 25-70 (NEW)

Ph III of LYL314 in 2L for R/R B-Cell NHL

Accrual: 0/7

Coord: Michael K.

Relapsed/Refractory

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

Cell Therapy

Molecularly-Driven

3rd Line+

2+ Lines

UCI 22-134

Oral AS-1763 in patients w/
previously treated CLL/SLL or NHL

Accrual: 5/9

Coord: Kelsey McAbee

Relapsed/Refractory

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

EBV+

Molecularly-Driven

2 + Lines

3rd Line+

UCI 22-134
Oral AS-1763 in patients w/
previously treated CLL/SLL or NHL
Accrual: 5/9
Coord: Kelsey McAbee

Newly diagnosed

■ Open to Accrual
 ■ Low Accruing
 ■ Pending Activation/Suspended

High-Risk

S1925

Venetoclax+Obnutumab early intervention vs. delayed therapy in asymptomatic high-risk CLL/SLL

Accrual: 5/10

Coord: Michael Kunicki

Front Line

UCI 25-192 (New)

Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared with Venetoclax Plus Acalabrutinib in Patient with Previously Untreated CLL

Accrual: 0/7

Coord: TBA

Follow Up

UCI 25-205 (New)

Long-term follow-up of ibrutinib plus venetoclax in patients with treatment-naïve CLL/SLL

Accrual: 0/6

Coord: TBA

Relapsed/Refractory

■ Open to Accrual

■ Low Accruing

■ Pending Activation/Suspended

3rd Line+**UCI 22-134**

Oral AS-1763 in patients w/
previously treated CLL/SLL or NHL

Accrual: 5/9

Coord: Kelsey McAbee

2nd Line+**UCI 24-190**

A Phase III Study of Sonrotoclax Plus
Anti-CD20 Antibody Therapies Versus
Venetoclax + Rituximab in Patients With
R/R CLL/SLL

Accrual: 1/7

Coord: Kelsey McAbee

UCI 26-36 (New)

A Single-arm, Phase 2, Open-label, Multicenter Study
to Evaluate NX-5948 in Adults with
Relapsed/Refractory (R/R) Chronic Lymphocytic
Leukemia (CLL) or Small Lymphocytic Lymphoma
(SLL) Previously Exposed to a Bruton's Tyrosine
Kinase Inhibitor (BTKi) and a B-cell Lymphoma-2
Inhibitor (BCL-2i)

Accrual: 0/5

Coord: Stephanie Osorio

UCI 24-32

Epcoritamab as Consolidation Therapy
for High-risk Patients with Chronic
Lymphocytic Leukemia on Bruton
Tyrosine Kinase Inhibitor

Accrual: 0/24

Coord: Kelsey McAbee

UCI 25-148 (New)

IgPro20 in Subjects with Chronic
Lymphocytic Leukemia / Small
Lymphocytic Lymphoma and
Secondary Hypogammaglobulinemia
Experiencing Severe or Recurrent
Infections

Accrual: 0/5

Coord: Stephanie Osorio

Relapsed/Refractory

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

Molecularly-Driven

Consolidation

S2114

Consolidation therapy following
CD19 CAR T-cell tx

Accrual: 0/6

Coord: Michael Kunicki

2+ Lines

Relapsed/Refractory

■ Open to Accrual
 ■ Low Accruing
 ■ Pending Activation/Suspended

Molecularly-Driven

Cell Therapy

UCI 23-114

Safety and Efficacy of IMPT-314, a CD19/20 Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy in B-cell NHL

Accrual: 9/10

Coord: Michael Kunicki

2+ Lines

3rd line+

UCI 22-134

Oral AS-1763 in patients w/ previously treated CLL/SLL or NHL

Accrual: 5/9

Coord: Kelsey McAbee

UCI 24-174

Efficacy and Safety of ITK Inhibitor Soquelitinib Versus Physician's Choice Standard of Care Treatment (Selected Single Agent) in Participants with Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

Accrual: 0/5

Coord: Melisa Duvnjak

UCI 21-95

Acalabrutinib Maintenance Following Cellular Therapy for LBCL Patients at High Risk for Relapse

Accrual: 0/5

Coord: Michael Kunicki

Relapsed/Refractory

■ Open to Accrual
 ■ Low Accruing
 ■ Pending Activation/Suspended

2nd Line+**UCI 21-99**

ONO-4685 given as
monotherapy

Accrual: 5/10

Coord: Melisa Duvnjak

UCI 24-188

PHASE 2 STUDY OF PTX-100
MONOTHERAPY IN PATIENTS
WITH R/R CUTANEOUS T-CELL
LYMPHOMA

Accrual: 0/5

Coord: Melisa Duvnjak

UCI 25-74

A Multicenter, Open-Label,
First-In-Human, Multiple
Expansion Cohort, Phase I/II
Study to Evaluate the Safety and
Efficacy of DR-01 in Subjects
with LGLL or Cytotoxic
Lymphomas

Accrual: 3/5

Coord: Melisa Duvnjak

UCI 25-142

Study of KK2223 in Participants
with Relapsed or Refractory T-cell
Non-Hodgkin Lymphoma

Accrual: 0/5

Coord: Judit Castellanos, Stephanie
Osorio

Newly Diagnosed

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

Treatment-Naive

Post-Induction Treatment

UCI 22-18
Investigation of MRD in patients with treatment-naive systemic T cell lymphoma tx w/ a brentuximab-containing regimen

Accrual: 0/5

Coord: TBD

ECOG EA4232
Phase III Study to Evaluate ASCT in Patients with PTCL that Achieved a First CR1 Following Induction Therapy (PTCL-STAT)

Accrual: 0/5

Coord: TBD

Relapsed/Refractory

■ Open to Accrual
 ■ Low Accruing
 ■ Pending Activation/Suspended



UCI 25-142
 Study of KK2223 in Participants with Relapsed or Refractory T-cell Non-Hodgkin Lymphoma
 Accrual: 0/5
 Coord: Melisa Duvnjak

UCI 21-99
 ONO-4685 given as monotherapy
 Accrual: 5/10
 Coord: Melisa Duvnjak

UCI 24-174
 ITK Inhibitor Soquelitinib vs. MD Choice SOC Tx in Participants w/ R/R PTCL NOS, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
 Accrual: 0/5
 Coord: Melisa Duvnjak

Relapsed/Refractory

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended



UCI 25-74
Open-Label, First-In-Human,
Multiple Expansion Cohort,
Phase I/II Study to Evaluate the
Safety & Efficacy of DR-01 in
Subjects with LGLL or Cytotoxic
Lymphomas
Accrual: 3/5
Coord: Melisa Duvnjak

Newly Diagnosed

COG-AHOD2131

Standard Therapy with
Immuno-oncology Therapy
for Newly Diagnosed Stage I
and II Classical Hodgkin
Lymphoma

Accrual: 2/5

Coord: Melisa Duvnjak

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

Relapsed/Refractory

≥ 1 Line

UCI 25-21 (NEW)

Pembrolizumab and GVD with
ctDNA-guided Consolidation in
Patients with Relapsed or
Refractory Classic Hodgkin
Lymphoma

Accrual: 0/5

Coord: TBA

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

Molecularly-Driven

Basket study

Relapsed/Refractory

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

ETCTN-10717

Phase Ib/II Trial of Pidnarulex in
MYC Aberrant Lymphoma

Accrual: 0/2

Coord: Melisa Duvnjak

CAR-T Products

Allogeneic

NHL

UCI 23-114

Safety & Efficacy of LYL314, a CD19/20 Bispecific CAR-T for R/R B-Cell NHL

Accrual: 9/10

Coord: Michael K.

ALL

UCI 25-209 (NEW)

UCART22 (allogeneic Anti-CD22 CAR-T) in R/R CD22+ B-ALL

Accrual: 0/3

Coord: Michael K.

Open to Accrual

Low Accruing

Pending Activation/Suspended

Autologous

NHL

MM

UCI 25-62

EAP for Vicleucel (ide-cel) that is Nonconforming for Commercial Release

Accrual: 0/5

Coord: Michael K.

UCI 25-220

AZD0120 Compared with Continuous Standard Therapy in NDMM Who Are Not Planned to Receive ASCT as Initial Therapy

Accrual: 0/5

Coord: Michael K.

UCI 25-63

EAP for Lisocabtagene Maraleucel (liso-cel) that is Nonconforming for Commercial Release

Accrual: TBA

Coord: Michael K.

UCI 25-221

AZD0120 Compared with Continuous Standard Therapy in NDMM Who Are ASCT Eligible

Accrual: TBA

Coord: Michael K.

CAR-T Products

Allogeneic

NHL

ALL

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

Autologous

NHL

MM

UCI 24-62

Ph III GPRC5D-directed CAR T Cell Therapy in Pts w/ R/R & Lenalidomide-exposed MM (QUINTESSENTIAL-2)

Accrual: 0/5

Coord: Michael K.

Supportive Care

■ Open to Accrual
 ■ Low Accruing
 ■ Pending Activation/Suspended

Autologous

UCI 23-193
CTO1681 for the Prevention & Treatment of CRS in pts w/ DLBCL receiving CAR-T Therapy

Accrual: 1/5

Coord: Michael K.

Alliance-A062102
Iberdomide Maintenance Therapy Following Ide-Cel CAR-T in R/R Multiple Myeloma

Accrual: 0/5

Coord: Michael K.

S2114
Consolidation Therapy Following CD19 CAR-T for R/R Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma

Accrual: 1/6

Coord: Michael K.

UCI 24-110
HaploDonor-QoL: Donor Health-Related Quality-of-Life and Physician Decision-Making in the Context of Haploidentical Hematopoietic Stem Cell Transplantation

Accrual: 0/7

Coord: Mario Diaz

Allogeneic

UCI 21-90
Risk-ADAPTEd conditioning regimen for AHST

Accrual: 32/48

Coord: Mario Diaz

UCI 22-188
Prospective evaluation of CMV-TCIP directed Letemovir ppx after AHCT

Accrual: 20/50

Coord: Mario Diaz

UCI 24-131
Vimseltinib in Adults With Active Chronic GVHD After Failure of Prior Systemic Therapy

Accrual: 0/5

Coord: Mike K.

UCI 25-139 (NEW)
Efficacy of SER-155 to Reduce Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation

Accrual: 0/5

Coord: TBD

LTFU

Autologous

UCI 21-184

Long-term safety of CAR-T
inpatient w/ heme malignancies

Accrual: 6/7

Coord: Michael Kunicki

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

Allogeneic

UCI 24-110

HaploDonor-QoL: Donor Health-Related Quality-of-
Life and Physician Decision-Making in the Context
of Haploidentical Hematopoietic Stem Cell
Transplantation

Accrual: 0/7

Coord: Mario Diaz

Other

Open to Accrual

Low Accruing

Pending Activation/Suspended

UCI 14-89

Hematologic Malignancies Biorepository for human research

Accrual: 322/500

Coord: Helen Huang

UCI 22-194

A Retrospective analysis of L-carnitine for Treatment and/or Prevention of L-Asparaginase Hepatotoxicity during Induction or Salvage Chemotherapy for Hematologic Malignancies

Accrual: TBA

Coord: TBD

UCI 25-195 (NEW)

Clinical utility Karius testing for diagnosis & management of suspected infections in adult immunocompromised patients

Accrual: 0/10

Coord: TBD

UCI 25-198 (NEW)

A multicenter protocol for haploidentical stem cell transplantation: Optimization of transplant outcomes in a collaborative consortium

Accrual: TBA

Coord: TBD

UCI 25-226 (NEW)

PROSPECTIVE OBSERVATIONAL INTERNATIONAL REGISTRY OF PATIENTS WITH NEWLY DIAGNOSED BURKITT LYMPHOMA

Accrual: 0/5

Coord: TBD

UCI 26-51 (NEW)

A Phase 3, Prospective, Open-label, Multicenter, Single-arm study to investigate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Subjects with Secondary Immune Deficiency due to Hematologic Malignancies Treated with B-cell Depleting Therapies

Accrual: TBD

Coord: TBD